European Archives - Page 483 of 1019 - European Medical Journal

EMJ Oncology 9 [Supplement 3] 2021 Feature Image

Reimagining Treatment of HR+, HER2- Early Breast Cancer

Dr Prat explained that there are three main variables that should be considered when determining the risk of recurrence for…

EMJ Oncology 9 [Supplement 3] 2021 Feature Image

EMJ Oncology 9 [Supplement 3] 2021

DURING a satellite symposium at the virtual 17th St Gallen International Breast Cancer Conference 2021, Dr Aleix Prat and Dr Giuseppe…

Prominent Cutaneous Manifestation of COVID-19: A Case Report

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen and the subsequent coronavirus disease (COVID-19) mainly affect the lung…

A New PET Tracer That is Safe and Clearly Detects Arthritis

Academics at the Turku PET Centre, University of Turku, Finland, developed a novel PET tracer that facilitates early detection of inflammatory foci…

Could a New Imaging Technique Improve Detection of Epileptic Foci?

New research from the University of Virginia School of Medicine, Charlottesville, Virginia, USA, has identified an advanced imaging technique to help…

EMJ Podcast: People with Parkinson’s

Russ Bradford and Charlotte Allen, Founders of Parkinson’s Concierge, discuss their personal experiences with the disease, the work they do to raise awareness of it, and how they feel healthcare systems could better support people living with Parkinson’s.

To be or to belong?

Diversity and inclusion (D&I) has become a core focus for pharma, but how can it go one step further and cultivate a culture of belonging?

Harnessing AI for Marketing ROI

we look at how AI tools can boost traditional marketing campaigns’ productivity, improve targeting, and deliver significant business value.

HBA's Laurie Cooke on Creating a Culture of Belonging

In what ways can we hold each other accountable, not just for the number of women in leadership, but how women, and especially women of colour, are represented and supported throughout the hiring pipeline?

Brexit revisited: how has the life sciences fared?

After years of tough negotiations, the UK has left the European Union. GOLD explores how pharmaceutical innovation has been affected as the UK works to replace EU resources and make use of its new-found regulatory freedom